» Articles » PMID: 36013073

The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Aug 26
PMID 36013073
Authors
Affiliations
Soon will be listed here.
Abstract

Antibody-mediated rejection (AMR) of liver allograft transplantation was considered as anecdotal for many decades. However recently, AMR has gained clinical awareness as a potential cause of chronic liver injury, leading to liver allograft fibrosis and eventual graft failure. (1) Methods: Literature on chronic AMR (cAMR) in pediatric post-liver transplant patients was reviewed for epidemiologic data, physiopathology, diagnosis, and treatment approaches. (2) Results: Accurate incidence of cAMR in pediatric liver transplantation remains unknown. Diagnostic criteria of cAMR were suggested by the Banff Working Group in 2016 and are based on standardized histopathological findings, C4d staining pattern, associated with the presence of donor-specific antibodies (DSA). Physio-pathological mechanisms are not clear for the technically difficult-to-obtain animal models reproducing cAMR. Treatment protocols are not established, being limited to case reports and case series, based on experience in ABO incompatible transplantation and kidney transplantation. Immunosuppression compliance with adequate dose adjustment may prevent cAMR. Conversion of Cyclosporine to Tacrolimus may improve pathological findings if treated in early phase. The association of steroids, Mycophenolate Mofetil (MMF) and mTOR inhibitors have shown some synergistic effects. Second-line treatments such as intravenous immunoglobulin (IVIG) and plasma exchange may decrease antibody titers based on ABO incompatible transplant protocols. The use of anti-CD20 (Rituximab) and proteasome inhibitors (Bortezomib) is controversial due to the lack of qualified studies. Therefore, multicenter randomized trials are needed to establish the best therapeutic strategy. In refractory cases, re-transplantation is the only treatment for allograft failure. (3) Conclusions: This literature review collects recent clinical, histopathological, and therapeutical advances of cAMR in liver allograft transplantation of pediatric patients. There are many physio-pathological aspects of cAMR to be clarified. Further efforts with multicenter prospective protocols to manage patients with cAMR are needed to improve its outcome.

Citing Articles

Role of mTOR Inhibitors in Pediatric Liver Transplant Recipients: A Systematic Review.

Moghadamnia M, Dashti-Khavidaki S, Alimadadi H Paediatr Drugs. 2024; 26(6):673-693.

PMID: 39251556 DOI: 10.1007/s40272-024-00648-4.


Design and evaluation of an educational mobile program for liver transplant patients.

Langarizadeh M, Moghbeli F, Ahmadi S, Langarizadeh M, Sayadi M, Sarpourian F BMC Health Serv Res. 2023; 23(1):974.

PMID: 37684647 PMC: 10492268. DOI: 10.1186/s12913-023-09989-1.


Comparative effects of hepatocyte growth factor and tacrolimus on acute liver allograft early tolerance.

Chen Q, Yang Z, Lin H, Lai J, Hu D, Yan M Front Immunol. 2023; 14:1162439.

PMID: 37614233 PMC: 10444199. DOI: 10.3389/fimmu.2023.1162439.

References
1.
Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S . Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl. 2012; 18(11):1333-42. DOI: 10.1002/lt.23534. View

2.
Wozniak L, Hickey M, Venick R, Vargas J, Farmer D, Busuttil R . Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. Transplantation. 2015; 99(7):1416-22. PMC: 5283576. DOI: 10.1097/TP.0000000000000796. View

3.
Musat A, Agni R, Wai P, Pirsch J, Lorentzen D, Powell A . The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant. 2011; 11(3):500-10. PMC: 3357120. DOI: 10.1111/j.1600-6143.2010.03414.x. View

4.
Wu Y, Huang M, Sun H, Zhou X, Zhou R, Gu G . Role of Innate Immunity in Pediatric Post-transplant Idiopathic Liver Fibrosis. Front Immunol. 2020; 11:2111. PMC: 7642407. DOI: 10.3389/fimmu.2020.02111. View

5.
Guerra M, Naini B, Scapa J, Reed E, Busuttil R, Cheng E . Obliterative portal venopathy: A histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts. Pediatr Transplant. 2018; 22(2). DOI: 10.1111/petr.13124. View